BR0010225A - Composto de amida, processo para prepará-lo, composição farmacêutica compreendendo dito composto, método de tratamento e uso - Google Patents
Composto de amida, processo para prepará-lo, composição farmacêutica compreendendo dito composto, método de tratamento e usoInfo
- Publication number
- BR0010225A BR0010225A BR0010225-3A BR0010225A BR0010225A BR 0010225 A BR0010225 A BR 0010225A BR 0010225 A BR0010225 A BR 0010225A BR 0010225 A BR0010225 A BR 0010225A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- preparing
- treatment
- pharmaceutical composition
- amide
- Prior art date
Links
- -1 Amide compound Chemical class 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPP8912A AUPP891299A0 (en) | 1999-02-26 | 1999-02-26 | New 6-membered cyclic compounds |
| PCT/JP2000/000601 WO2000051970A1 (en) | 1999-02-26 | 2000-02-03 | Amide compounds for the potentiation of cholinergic activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0010225A true BR0010225A (pt) | 2002-01-22 |
Family
ID=3813111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0010225-3A BR0010225A (pt) | 1999-02-26 | 2000-02-03 | Composto de amida, processo para prepará-lo, composição farmacêutica compreendendo dito composto, método de tratamento e uso |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1159258B1 (enExample) |
| JP (1) | JP4089159B2 (enExample) |
| KR (1) | KR100620406B1 (enExample) |
| CN (1) | CN1170814C (enExample) |
| AR (1) | AR029618A1 (enExample) |
| AT (1) | ATE282022T1 (enExample) |
| AU (2) | AUPP891299A0 (enExample) |
| BR (1) | BR0010225A (enExample) |
| CA (1) | CA2371827C (enExample) |
| DE (1) | DE60015732T2 (enExample) |
| DK (1) | DK1159258T3 (enExample) |
| ES (1) | ES2226775T3 (enExample) |
| HK (1) | HK1044934B (enExample) |
| HU (1) | HUP0200116A3 (enExample) |
| PT (1) | PT1159258E (enExample) |
| RU (1) | RU2211215C2 (enExample) |
| TR (1) | TR200102494T2 (enExample) |
| TW (1) | TWI225856B (enExample) |
| WO (1) | WO2000051970A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2351347A1 (en) | 1998-11-23 | 2000-06-02 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
| CN100370990C (zh) | 1998-12-24 | 2008-02-27 | 詹森药业有限公司 | 控释加兰他敏组合物 |
| MY136316A (en) | 2001-02-13 | 2008-09-30 | Sanofi Aventis Deutschland | Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical. |
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| PE20020856A1 (es) | 2001-02-13 | 2002-11-11 | Aventis Pharma Gmbh | 1,2,3,4-tetrahidronaftil aminas aciladas |
| TWI241190B (en) | 2001-02-13 | 2005-10-11 | Aventis Pharma Gmbh | 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical |
| US6984647B2 (en) * | 2002-05-17 | 2006-01-10 | Janssen Pharmaceutica N.V. | Aminotetralin-derived urea modulators of vanilloid VR1 receptor |
| JP5036310B2 (ja) | 2003-08-06 | 2012-09-26 | セノミックス インコーポレイテッド | 新規な風味、風味改質剤、味覚剤、味覚向上剤、旨味および甘味味覚剤、および／またはそれらの向上剤および使用 |
| EP3398452B1 (en) | 2006-04-21 | 2024-10-02 | Firmenich Incorporated | Comestible compositions comprising high potency savory flavorants |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| UY32442A (es) | 2009-02-13 | 2010-09-30 | Sanofi Aventis | Nuevos indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento |
| JP2025066196A (ja) * | 2022-03-14 | 2025-04-23 | 国立大学法人東北大学 | 認知機能改善剤 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR8287M (enExample) * | 1968-12-31 | 1970-11-09 | ||
| US4797419A (en) * | 1986-11-03 | 1989-01-10 | Warner-Lambert Company | Method of treating the symptoms of senile cognitive decline employing di- or trisubstituted urea cholinergic agents |
| EP0306375A1 (fr) * | 1987-08-07 | 1989-03-08 | Synthelabo | Dérivés de[(pipéridinyl-4)méthyl]-2 tétrahydro-1,2,3,4 isoquinoléine, leur préparation et leur application en thérapeutique |
| IL90279A (en) * | 1988-05-24 | 1995-03-30 | American Home Prod | Piperazinyl carboxamide derivatives, their preparation and pharmaceutical com¦ositions containing them |
| GB8917687D0 (en) * | 1989-08-02 | 1989-09-20 | Fujisawa Pharmaceutical Co | Aminopiperazine derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
| RU2024507C1 (ru) * | 1991-11-18 | 1994-12-15 | Евгений Яковлевич Левитин | 5-хлор-2-пиридиламид-4-нитро-n-(карбоксиметил)антраниловой кислоты, проявляющий противовоспалительную активность |
| JPH06107544A (ja) * | 1992-09-29 | 1994-04-19 | Taisho Pharmaceut Co Ltd | コリン作動性神経不全の改善・治療薬 |
| JPH06298732A (ja) * | 1993-02-16 | 1994-10-25 | Taisho Pharmaceut Co Ltd | インドール誘導体 |
-
1999
- 1999-02-26 AU AUPP8912A patent/AUPP891299A0/en not_active Abandoned
-
2000
- 2000-02-03 TR TR2001/02494T patent/TR200102494T2/xx unknown
- 2000-02-03 AT AT00902080T patent/ATE282022T1/de not_active IP Right Cessation
- 2000-02-03 CA CA002371827A patent/CA2371827C/en not_active Expired - Fee Related
- 2000-02-03 HU HU0200116A patent/HUP0200116A3/hu unknown
- 2000-02-03 RU RU2001126120/04A patent/RU2211215C2/ru not_active IP Right Cessation
- 2000-02-03 DK DK00902080T patent/DK1159258T3/da active
- 2000-02-03 ES ES00902080T patent/ES2226775T3/es not_active Expired - Lifetime
- 2000-02-03 AU AU23257/00A patent/AU766655B2/en not_active Ceased
- 2000-02-03 EP EP00902080A patent/EP1159258B1/en not_active Expired - Lifetime
- 2000-02-03 KR KR1020017010325A patent/KR100620406B1/ko not_active Expired - Fee Related
- 2000-02-03 JP JP2000602198A patent/JP4089159B2/ja not_active Expired - Fee Related
- 2000-02-03 DE DE60015732T patent/DE60015732T2/de not_active Expired - Lifetime
- 2000-02-03 HK HK02106646.3A patent/HK1044934B/zh not_active IP Right Cessation
- 2000-02-03 WO PCT/JP2000/000601 patent/WO2000051970A1/en not_active Ceased
- 2000-02-03 CN CNB008043035A patent/CN1170814C/zh not_active Expired - Fee Related
- 2000-02-03 PT PT00902080T patent/PT1159258E/pt unknown
- 2000-02-03 BR BR0010225-3A patent/BR0010225A/pt not_active Application Discontinuation
- 2000-02-14 TW TW089102410A patent/TWI225856B/zh not_active IP Right Cessation
- 2000-02-24 AR ARP000100793A patent/AR029618A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2371827C (en) | 2008-06-10 |
| HK1044934B (zh) | 2005-06-03 |
| TWI225856B (en) | 2005-01-01 |
| AU766655B2 (en) | 2003-10-23 |
| DE60015732T2 (de) | 2005-03-31 |
| JP2002538132A (ja) | 2002-11-12 |
| RU2211215C2 (ru) | 2003-08-27 |
| WO2000051970A1 (en) | 2000-09-08 |
| AU2325700A (en) | 2000-09-21 |
| ES2226775T3 (es) | 2005-04-01 |
| PT1159258E (pt) | 2005-02-28 |
| TR200102494T2 (tr) | 2002-01-21 |
| CN1170814C (zh) | 2004-10-13 |
| EP1159258A1 (en) | 2001-12-05 |
| JP4089159B2 (ja) | 2008-05-28 |
| HK1044934A1 (en) | 2002-11-08 |
| HUP0200116A3 (en) | 2002-11-28 |
| DK1159258T3 (da) | 2005-02-14 |
| EP1159258B1 (en) | 2004-11-10 |
| DE60015732D1 (de) | 2004-12-16 |
| AUPP891299A0 (en) | 1999-03-25 |
| ATE282022T1 (de) | 2004-11-15 |
| KR20010102140A (ko) | 2001-11-15 |
| AR029618A1 (es) | 2003-07-10 |
| CN1341095A (zh) | 2002-03-20 |
| CA2371827A1 (en) | 2000-09-08 |
| KR100620406B1 (ko) | 2006-09-13 |
| HUP0200116A2 (hu) | 2002-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0517423A (pt) | composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto | |
| BRPI0409227B8 (pt) | "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)" | |
| BR9713465A (pt) | Inibidores metalotprotease de amina cìclica sibstituìda | |
| BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
| BRPI0417947A (pt) | composto, composição farmacêutica, fabricação de um medicamento para o uso no tratamento e/ou prevenção de um metabólico distúrbio, e, formulação farmacêutica | |
| BR0313160A (pt) | Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto | |
| BR0312729A (pt) | Novos derivados de indol-3-enxofre | |
| BR0315580A (pt) | Derivados de metileno uréia | |
| BR0010555A (pt) | Inibidores de neuraminidases | |
| BR0309964A (pt) | Derivados anticonvulsivos de sulfamoto substituìdo | |
| BR9808953A (pt) | Composto, processo para tratar um distúrbio mediado pela ciclooxigenase-2 em um paciente, e, composição farmacêutica | |
| BR9914451A (pt) | Composto de oxazol, processo para sua preparação, composição farmacêutica compreendendo dito composto, uso da composição e métodos de tratamento | |
| AR011116A1 (es) | Compuesto derivado de n-hidroxi-beta-sulfonil propionamida y composicion farmaceutica que lo contiene | |
| BRPI0921701B8 (pt) | Cefarosporina tendo um grupo catecol, seu uso e composição farmacêutica que a compreende | |
| BR0315047A (pt) | Composto, composição fermacêutica que compreende o mesmo, processo para a preparação da composição farmacêutica, utilização dos compostos, método de tratamento e processo para a preparação do composto | |
| BR0206433A (pt) | Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto | |
| BR0314113A (pt) | Derivados de amino propanol | |
| BR0313880A (pt) | composto, pró-droga, composição farmacêutica, composição e método para modular receptor de cálcio, método para prevenir ou tratar doenças ósseas, e, uso do composto ou um sal deste ou uma pró-droga deste | |
| DE60112766D1 (de) | Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen | |
| BR0209127A (pt) | compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos | |
| BRPI0407695A (pt) | compostos, processo para a preparação de um composto, composições farmacêuticas que compreendem o composto, utilização dos compostos e processo de tratamento para diabetes do tipo 2 | |
| BRPI0514448A (pt) | derivados do ácido bifenil-oxiacético para uso no tratamento de doenças respiratórias | |
| BR0010225A (pt) | Composto de amida, processo para prepará-lo, composição farmacêutica compreendendo dito composto, método de tratamento e uso | |
| BR0313727A (pt) | Derivados de isoquinolina como inibidores de metaloproteinase da matriz | |
| BR0309558A (pt) | Derivados de quinazolina e medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) Free format text: TRANSFERIDO POR FUSAO DE: FUJISAWA PHARMACEUTICAL CO., LTD. |
|
| B25D | Requested change of name of applicant approved |
Owner name: ASTELLAS PHARMA INC. (JP) Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD. |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PRESENTE PEDIDO DE ACORDO COM OS ARTIGOS 8O, 10 (VIII), 11, 13, 24 E 25 DA LPI. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |